Ideaya Biosciences Inc. | Mid-cap | Healthcare
$24.61
-1.28%
| Ideaya Biosciences Stock Comparison:
Ideaya Biosciences vs VertexIdeaya Biosciences vs AlnylamIdeaya Biosciences vs BridgeBio PharmaIdeaya Biosciences vs MadrigalIdeaya Biosciences vs Roivant SciencesIdeaya Biosciences vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -88.8M
Net Income -77.5M
EPS (Diluted) $-0.88

Balance Sheet Metrics

Total Assets 1.1B
Total Liabilities 76.5M
Shareholders Equity 1.0B
Debt to Equity 0.07

Cash Flow Metrics

Operating Cash Flow -57.5M
Free Cash Flow -61.7M

Revenue & Profitability Trend

Ideaya Biosciences Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i7.0M23.4M50.9M27.9M19.5M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i294.7M129.5M89.5M58.2M39.7M
Selling, General & Administrative i39.3M28.3M23.9M20.1M15.2M
Other Operating Expenses i-----
Total Operating Expenses i334.0M157.8M113.4M78.2M54.9M
Operating Income i-327.0M-134.4M-62.5M-50.3M-35.3M
Operating Margin % i-4,671.1%-574.9%-122.7%-179.9%-180.9%
Non-Operating Items
Interest Income i52.5M21.5M3.8M506.0K849.0K
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i-274.5M-113.0M-58.7M-49.8M-34.5M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-274.5M-113.0M-58.7M-49.8M-34.5M
Net Margin % i-3,921.1%-483.0%-115.2%-178.1%-176.6%
Key Metrics
EBITDA i-323.1M-130.4M-59.0M-47.2M-34.0M
EPS (Basic) i$-3.36$-1.96$-1.42$-1.41$-1.40
EPS (Diluted) i$-3.36$-1.96$-1.42$-1.41$-1.40
Basic Shares Outstanding i8167806957519929414446963525244324721775
Diluted Shares Outstanding i8167806957519929414446963525244324721775

Income Statement Trend

Ideaya Biosciences Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i84.4M157.0M68.6M92.0M72.0M
Short-term Investments i591.9M368.1M296.2M154.7M211.5M
Accounts Receivable i3.0K18.0K211.0K1.1M1.9M
Inventory i-----
Other Current Assets13.4M7.5M5.4M3.1M3.1M
Total Current Assets i689.7M532.6M370.5M251.0M288.6M
Non-Current Assets
Property, Plant & Equipment i32.3M13.7M12.2M10.3M10.0M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets805.0K782.0K205.0K397.0K188.0K
Total Non-Current Assets i434.4M116.7M17.5M130.4M9.7M
Total Assets i1.1B649.3M388.0M381.3M298.3M
Liabilities
Current Liabilities
Accounts Payable i15.4M6.6M4.3M2.1M953.0K
Short-term Debt i298.0K1.7M1.9M1.7M1.5M
Current Portion of Long-term Debt-----
Other Current Liabilities----18.0K
Total Current Liabilities i46.1M27.1M31.7M45.2M38.6M
Non-Current Liabilities
Long-term Debt i18.9M1.1M1.6M3.5M5.2M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities----12.0K
Total Non-Current Liabilities i18.9M1.1M6.8M34.7M61.4M
Total Liabilities i64.9M28.2M38.5M79.8M100.0M
Equity
Common Stock i9.0K7.0K5.0K4.0K3.0K
Retained Earnings i-622.8M-348.4M-235.4M-176.7M-127.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.1B621.1M349.5M301.5M198.3M
Key Metrics
Total Debt i19.2M2.9M3.5M5.2M6.7M
Working Capital i643.6M505.5M338.7M205.8M250.0M

Balance Sheet Composition

Ideaya Biosciences Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-274.5M-113.0M-58.7M-49.8M-34.5M
Depreciation & Amortization i3.8M4.0M3.5M3.0M1.4M
Stock-Based Compensation i34.7M18.5M11.6M8.2M3.6M
Working Capital Changes i6.9M-12.8M-44.0M-21.8M81.9M
Operating Cash Flow i-229.0M-103.3M-87.5M-60.3M52.4M
Investing Activities
Capital Expenditures i-3.9M-2.4M-3.4M-2.6M-493.0K
Acquisitions i-----
Investment Purchases i-1.2B-596.0M-255.8M-315.0M-242.3M
Investment Sales i692.6M439.9M225.8M248.0M96.6M
Investing Cash Flow i-502.6M-158.5M-33.4M-69.7M-146.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i663.6M351.9M95.0M143.3M127.2M
Free Cash Flow i-251.4M-117.6M-90.6M-58.4M55.0M
Net Change in Cash i-67.9M90.2M-26.0M13.3M33.4M

Cash Flow Trend

Ideaya Biosciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.32
Forward P/E -9.05
Price to Book 2.25
Price to Sales 308.13
PEG Ratio -0.25

Profitability Ratios

Profit Margin 0.00%
Operating Margin -5,488.94%
Return on Equity -35.09%
Return on Assets -23.84%

Financial Health

Current Ratio 12.39
Debt to Equity 2.77
Beta 0.12

Per Share Data

EPS (TTM) $-3.84
Book Value per Share $10.95
Revenue per Share $0.08

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
idya2.2B-7.322.25-35.09%0.00%2.77
Vertex 101.2B28.085.8922.77%31.86%8.89
Alnylam 61.1B-213.71244.95-257.83%-12.96%1,093.31
BridgeBio Pharma 9.8B-17.78-5.4936.76%98.25%-1.04
Madrigal 9.6B-19.7413.80-36.30%-54.68%17.81
Roivant Sciences 9.6B1.952.21-18.15%96.86%2.07

Financial data is updated regularly. All figures are in the company's reporting currency.